[68Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 115-122

  Knetsch, Peter A ^a   Zhai, Chuangyan ^a   Rangger, Christine ^a   Blatzer, Michael ^a   Haas, Hubertus ^a   Kaeopookum, Piriya ^b   Haubner, Roland ^a   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Thailand Ministry of Science and Technology   (Thailand)

Author keywords

68Ga; Bifunctional chelator; RGD; Siderophors; v 3 integrin

Indexed keywords

1,4,7 TRIAZACYCLONONANE,1 GLUTARIC ACID 4,7 ACETIC ACID ARGINYLGLYCYLASPARTIC ACID GA 68; FERRIC CHLORIDE; FUSARININE C(3 ARGINYLGLYCYLASPARTIC ACID) GA 68; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SIDEROPHORE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CHELATING AGENT; CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; FERRIC ION; FUSIGEN; GALLIUM; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; IN VITRO STUDY; ISOTOPE LABELING; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOCHEMISTRY; SOLID PHASE SYNTHESIS; CHEMISTRY; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CHELATING AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; FEASIBILITY STUDIES; FERRIC COMPOUNDS; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; INTEGRIN ALPHAVBETA3; ISOTOPE LABELING; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; SIDEROPHORES; TISSUE DISTRIBUTION;

EID: 84921307878     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.10.001     Document Type: Article

References (29)

1. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008, 3:67-77.
2. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 2007, 34:982-993.
3. 3 integrin expression. Eur J Nucl Med Mol Imaging 2008, 35:1507-1515.
4. Velikyan I. Prospective of 68Ga-radiopharmaceutical development. Theranostics 2014, 4:47-80.
5. Neilands J.B. Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 1995, 270:26723-26726.
6. 68Ga-siderophores for infection imaging. Nucl Med Biol 2012, 39:361-369.
7. 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur J Nucl Med Mol Imaging 2012, 39:1175-1183.
8. 68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: proof of principle. J Nucl Med 2010, 51:639-645.
9. Haubner R., Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009, 14:872-886.
10. Gaertner F.C., Kessler H., Wester H.J., Schwaiger M., Beer A.J. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med 2012, 39(Suppl. 1):S126-S138.
11. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
12. 3 integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
13. 68Ga. Eur J Nucl Med Mol Imaging 2005, 32:478-485.
14. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004, 15:61-69.
15. Schrettl M., Bignell E., Kragl C., Sabiha Y., Loss O., Eisendle M., et al. Distinct roles for intra- and extracellular siderophores during Aspergillus fumigatus infection. PLoS Pathog 2007, 3:1195-1207.
16. 99mTc]cRGD peptides labeled using different novel Tc-cores. Q J Nucl Med Mol Imaging 2007, 51:33-41.
17. Haas H. Iron - a key nexus in the virulence of aspergillus fumigatus. Front Microbiol 2012, 3:28.
18. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003, 44:1271-1281.
19. Dhungana S., Miller M.J., Dong L., Ratledge C., Crumbliss A.L. Iron chelation properties of an extracellular siderophore exochelin MN. J Am Chem Soc 2003, 125:7654-7663.
20. Notni J., Simecek J., Hermann P., Wester H.J. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J 2011, 17:14718-14722.
21. Notni J., Pohle K., Wester H.J. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res 2012, 2:28.
22. 68Ga. Appl Radiat Isot 2011, 69:942-946.
23. 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem 2012, 23:1712-1717.
24. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61:1781-1785.
25. 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011, 38:128-137.
26. 64Cu/NOTA-[D-Tyr6, βAla11, Thi13, Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Res 2012, 2:8.
27. Sosabowski J.K., Matzow T., Foster J.M., Finucane C., Ellison D., Watson S.A., et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 2009, 50:2082-2089.
28. Wester H.J., Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?. J Nucl Med 2005, 46:1940-1945.
29. Line B.R., Mitra A., Nan A., Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005, 46:1552-1560.